These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 971859)

  • 1. [Xanthinol nicotinate and bufenin hydrochloride in the treatment of gestosis].
    Cretti A; Jaworski S
    Ginekol Pol; 1976 Aug; 47(8):909-16. PubMed ID: 971859
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipids in pregnant patients with severe course of gestosis treated with xanthinol nicotinate and bufenin hydrochloride].
    Kuć A; Skrzydlewski Z
    Ginekol Pol; 1976 Apr; 47(4):379-82. PubMed ID: 177335
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of xanthinol nicotinate in patients with chronic ischemic heart disease].
    Sivkov II; Kukes VG; Borisov VG; Rudakov MA; Blistanova LS
    Ter Arkh; 1977; 49(1):30-3. PubMed ID: 867235
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug therapy of hyperlipemia. Experiences with xanthinol nicotinate retard-capsules in a general practice].
    Klimm HD
    Med Monatsschr; 1976 Apr; 30(4):178-80. PubMed ID: 958145
    [No Abstract]   [Full Text] [Related]  

  • 5. Thermographical follow-up during treatment of chronic ulcerations with iontophoresis with xanthinol nicotinate.
    van der Kuy A; Aarts NJ
    Bibl Radiol; 1975; (6):203-9. PubMed ID: 1180851
    [No Abstract]   [Full Text] [Related]  

  • 6. Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies.
    Afifi AM; Adnan M; Taha M; Amasha ME
    Curr Med Res Opin; 1979; 6(5):309-13. PubMed ID: 540521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of xanthinol nicotinate on the serum lipids and lipoproteins of patients with primary hyperlipoproteinemia Type IIb and IV].
    Haacke H; Parwaresch MR; Mäder C
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():829-32. PubMed ID: 1029294
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of a long-term study on the therapeutic effectiveness of xanthinol nicotinate in chronic hepatopathies].
    Dohrmann RE; Kessel ME
    Z Allgemeinmed; 1975 Sep; (26):1167-72. PubMed ID: 1226797
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical trial of xanthinol nicotinate in delayed form in the treatment of arteritis of the lower limbs].
    Niquet G; Dupont T
    Lille Med; 1976 Jan; 21(1 suppl 1):13-5. PubMed ID: 1256225
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute effect of xanthinol nicotinate on the muscle clearance of 133Xenon.
    Szilvási I; Molnár G
    Ther Hung; 1973; 21(3-4):114-6. PubMed ID: 4806418
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapy of hyperlipidemia with xanthinol nicotinate as opposed to low fat diet].
    Baumann J; Martschick R
    Med Welt; 1982 Jan; 33(4):139-41. PubMed ID: 7062844
    [No Abstract]   [Full Text] [Related]  

  • 12. Xantinol nicotinate in paralytic poliomyelitis.
    Saksena PN; Malik GK; Tandon OP
    Indian Pediatr; 1979 Dec; 16(12):1081-4. PubMed ID: 541073
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rehabilitation course in patients with peripheral and coronary angio-organopathies. Studies with special reference to serum uric acid and cholesterol under xanthinol nicotinate].
    Mensen H
    Ther Ggw; 1977 Oct; 116(10):1853-81. PubMed ID: 918880
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypolipidaemic effect of xantinol nicotinate: a clinical trial.
    Dhorranintra B; Khunawat P; Patalung BN; Prabhan C
    J Med Assoc Thai; 1983 May; 66(5):269-73. PubMed ID: 6348198
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological properties and clinical use of xanthinol nicotinate].
    Mashkovskiĭ MD; Iuzhakov SD; Absava GI; Erokhina LG; Lebedeva NV
    Klin Med (Mosk); 1984 Nov; 62(11):30-4. PubMed ID: 6097742
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bioavailability and tolerance of xanthinol nicotinate depot preparations. Comparison of a conventional 500 mg xanthinol nicotinate depot tablet with new 500 mg and 1 g depot tablets].
    von Schrader HW; Buscher G; Dierdorf D; Freytag A; Mügge H; Wolf D
    Arzneimittelforschung; 1985; 35(9):1468-72. PubMed ID: 4084347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical comparison of dextran 40 and xantinol nicotinate in the treatment of sudden deafness caused by shock waves (author's transl)].
    Martin G; Jacobs P
    Laryngol Rhinol Otol (Stuttg); 1977 Oct; 56(10):860-3. PubMed ID: 144224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of placebo and plain and slow-release tablets of xanthinol nicotinate on exercise tolerance in normal human subjects.
    Sharma PL
    Int J Clin Pharmacol Biopharm; 1978 Jan; 16(1):19-21. PubMed ID: 631966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Circulatory effects of xanthinol nicotinate in advanced pregnancy (author's transl)].
    Schwarz R; Retzke U; Lauckner W
    Zentralbl Gynakol; 1980; 102(8):446-51. PubMed ID: 7456902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.